Screener
BioCryst Pharmaceuticals BCRX Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031238
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Principal payments on finance lease liabilities | (345) | (516) |
| Net cash provided by financing activities | 412,552 | 529 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | (72) | 451 |
| Net increase in cash, and cash equivalents, and restricted cash | 82,041 | 558 |
| Cash, cash equivalents and restricted cash: | ||
| Beginning of period | 91,337 | 106,323 |
| End of period | $173,378 | $106,881 |
| Reconciliation of cash, cash equivalents and restricted cash: |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's net change in cash?
- BioCryst Pharmaceuticals (BCRX) reported net change in cash of $82.04M in Q1 2026.
- How has BioCryst Pharmaceuticals's net change in cash changed year-over-year?
- BioCryst Pharmaceuticals's net change in cash increased by 14602.7% year-over-year, from $558K to $82.04M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about BioCryst Pharmaceuticals's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude